Story
Huatai Securities Raises RMB 1.9 Billion in Oversubscribed Perpetual Bond Sale
Summary
The Chinese brokerage secured a 1.85% coupon rate on the perpetual subordinated bonds, which saw strong demand with a subscription ratio of 4.77 times from professional investors.
Huatai Securities (6886.HK) has completed the issuance of RMB 1.9 billion in perpetual subordinated bonds, locking in a coupon rate of 1.85% amid strong investor demand, according to a company announcement.
Offering Details
The issuance, which concluded on September 21, 2026, was met with robust interest from the market. The offering was 4.77 times oversubscribed, signaling significant appetite from professional investors targeted by the sale.
The final coupon rate of 1.85% was priced within the initial marketing range of 1.3% to 2.3%. Key details of the offering include:
- Issuer: Huatai Securities Co., Ltd.
- Issue Size: RMB 1.9 billion
- Final Coupon: 1.85%
- Subscription Ratio: 4.77 times
AdBond Structure and Context
This issuance is the second tranche of a larger debt program. In November 2025, Huatai Securities received approval from the China Securities Regulatory Commission (CSRC) to issue up to RMB 20 billion in perpetual subordinated bonds to professional investors.
The bonds have a base term of five years, with a five-year reset period for the interest rate. At the end of each five-year cycle, Huatai Securities has the option to either redeem the bonds in full or extend their term for another five-year period.
For financial institutions like brokerages, perpetual subordinated bonds are a key instrument for strengthening their capital base. The proceeds are typically used to replenish supplementary capital, which enhances the firm's capital adequacy and supports its overall operational and strategic objectives without diluting existing shareholder equity.
Read next
More on Stocks
AI Leaders Anthropic and OpenAI Take Divergent IPO Paths Amid Regulatory Debate
Leading AI firms Anthropic and OpenAI are navigating the complex landscape of potential government regulation as they plan their public market debuts, with each adopting a distinct strategy to manage investor perceptions and market timing.
Grail Shares Surge 35% as FDA Staff Finds No Major Issues With Galleri Cancer Test
Shares of Grail soared after U.S. Food and Drug Administration staff reviewers found no major safety or accuracy concerns with its Galleri multi-cancer blood test ahead of a key advisory panel meeting.
AMD Briefly Hits $1 Trillion Valuation on AI Optimism
The chipmaker became the fourth in the U.S. to reach the milestone as its stock surged, fueled by investor confidence in its strategy to compete in the artificial intelligence computing market.
GAC Unveils Plan to Launch 12 Electric Models in France by 2030
The Chinese automaker announced an aggressive European expansion, aiming to introduce 12 electric and hybrid vehicles and establish a 200-strong dealership network in France over the next six years.